Detalles de la búsqueda
1.
The impact of SBF2 on taxane-induced peripheral neuropathy.
PLoS Genet
; 18(1): e1009968, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34986146
2.
Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE.
Br J Cancer
; 130(8): 1348-1355, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38347093
3.
Racial Disparities in Breast Cancer: from Detection to Treatment.
Curr Oncol Rep
; 26(1): 10-20, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38100011
4.
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
J Natl Compr Canc Netw
; 21(6): 594-608, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37308117
5.
Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial.
Support Care Cancer
; 31(2): 139, 2023 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36707490
6.
Leveraging GWAS data derived from a large cooperative group trial to assess the risk of taxane-induced peripheral neuropathy (TIPN) in patients being treated for breast cancer: Part 2-functional implications of a SNP cluster associated with TIPN risk in patients being treated for breast cancer.
Support Care Cancer
; 31(3): 178, 2023 Feb 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36809570
7.
Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103).
Cancer
; 128(11): 2174-2181, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35285940
8.
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
Br J Cancer
; 126(2): 265-274, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34616010
9.
ASO Perspectives: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer: Never Stop Questioning.
Ann Surg Oncol
; 29(5): 2735-2738, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35182309
10.
The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity.
J Natl Compr Canc Netw
; 20(4): 417-425, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35390763
11.
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(4): 387-405, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35390769
12.
Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer.
Oral Dis
; 28(1): 193-201, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33274559
13.
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
Breast Cancer Res Treat
; 185(1): 135-144, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33025482
14.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34120223
15.
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
J Natl Compr Canc Netw
; 19(8): 915-921, 2021 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33878726
16.
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.
Breast Cancer Res
; 22(1): 131, 2020 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-33256829
17.
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.
Invest New Drugs
; 38(5): 1421-1429, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31984451
18.
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
J Natl Compr Canc Netw
; 18(3): 230-241, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32135517
19.
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
Lancet Oncol
; 20(3): 361-370, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30709633
20.
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Breast Cancer Res
; 21(1): 87, 2019 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31383035